{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:16Z","timestamp":1792048636979,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This single-center retrospective study aimed to evaluate the safety and efficacy of Tocilizumab (TOC) in children with polyarticular (pJIA) and systemic juvenile idiopathic arthritis (sJIA) who exhibited inadequate responses to disease-modifying antirheumatic drugs (DMARDs) and biological modifiers (bDMARDs). Conducted at the Department of Pediatric Rheumatology, National Institute of Geriatrics, Rheumatology, and Rehabilitation in Warsaw, Poland, between 2018 and 2022, the study enrolled 29 patients diagnosed with JIA based on International League of Associations for Rheumatology (ILAR) criteria. The cohort comprised 13 sJIA and 16 pJIA patients, aged 2-18 years, receiving TOC treatment for 24 months. Safety and efficacy assessments included analysis of medical documentation, laboratory tests (CRP, ESR, WBC), and Juvenile Disease Activity Score (JADAS) 71 at baseline, 3, 6, 12, and 24 months post-treatment initiation. Significant reductions in CRP and ESR levels were observed within three months, with sustained improvement in JADAS71 scores over the 24-month treatment period. A substantial majority, 73.07% of patients, achieved inactive disease status or low disease activity, highlighting T0C\u2019s effectiveness. Adverse effects were manageable, predominantly involving mild to moderate infections, with no serious adverse events or instances of macrophage activation syndrome (MAS). The study also noted a steroid-sparing effect of TOC, with a reduction in glucocorticoid usage among the cohort. Tocilizumab demonstrates substantial efficacy in reducing disease activity and improving clinical outcomes in patients with pJIA and sJIA, coupled with a favorable safety profile. These findings reinforce the role of TOC as a critical component of the therapeutic arsenal for JIA, offering hope for improved quality of life and disease management in this patient population.<\/jats:p>","DOI":"10.1007\/s00296-024-05711-4","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:02:25Z","timestamp":1727064145000},"page":"2949-2959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical outcomes of tocilizumab therapy in polyarticular and systemic juvenile idiopathic arthritis: a single-center analysis (2018-2022)"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3771-9356","authenticated-orcid":false,"given":"Agnieszka","family":"Gazda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8293-7993","authenticated-orcid":false,"given":"Iryna","family":"Naishtetik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Ko\u0142odziejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9665-0338","authenticated-orcid":false,"given":"Khrystyna","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-0389","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Ma\u0144czak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"W\u00f3jtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6853-8564","authenticated-orcid":false,"given":"Olga","family":"Krasowicz-Towalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-0083","authenticated-orcid":false,"given":"Piotr","family":"Gietka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"2","key":"5711_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rhuematol 31(2):390\u2013392International League of Associations for Rheumatology","journal-title":"J Rhuematol"},{"issue":"9563","key":"5711_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet (London England) 369(9563):767\u2013778. https:\/\/doi.org\/10.1016\/S0140-6736(07)60363-8","journal-title":"Lancet (London England)"},{"key":"5711_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"ML Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ (2014) Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J 12:13. https:\/\/doi.org\/10.1186\/1546-0096-12-13","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"5711_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ghir.2008.01.006","volume":"18","author":"SC Wong","year":"2008","unstructured":"Wong SC, MacRae VE, Gracie JA, McInnes IB, Galea P, Gardner-Medwin J, Ahmed SF (2008) Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. Growth Hormone IGF Research: Official J Growth Hormone Res Soc Int IGF Res Soc 18(5):369\u2013378. https:\/\/doi.org\/10.1016\/j.ghir.2008.01.006","journal-title":"Growth Hormone IGF Research: Official J Growth Hormone Res Soc Int IGF Res Soc"},{"issue":"1","key":"5711_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/ncprheum0084","volume":"2","author":"P Woo","year":"2006","unstructured":"Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2(1):28\u201334. https:\/\/doi.org\/10.1038\/ncprheum0084","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Suppl 1","key":"5711_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00296-018-3966-8","volume":"38","author":"L Rutkowska-Sak","year":"2018","unstructured":"Rutkowska-Sak L, Smolewska E, Zygmunt A, Kwiatkowska M, Gazda A, Consolaro A, Bovis F, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) (2018) The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatol Int 38(Suppl 1):315\u2013321. https:\/\/doi.org\/10.1007\/s00296-018-3966-8","journal-title":"Rheumatol Int"},{"issue":"4","key":"5711_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.5604\/12321966.1185780","volume":"22","author":"M T\u0142ustochowicz","year":"2015","unstructured":"T\u0142ustochowicz M, \u015aliwczy\u0144ski A, Iltchev P, Brzozowska M, Sierocka A, Marczak M, T\u0142ustochowicz W (2015) Juvenile idiopathic arthritis morbidity rate in rural and urban areas of Poland 2008\u20132012. Annals Agricultural Environ Medicine: AAEM 22(4):704\u2013707. https:\/\/doi.org\/10.5604\/12321966.1185780","journal-title":"Annals Agricultural Environ Medicine: AAEM"},{"key":"5711_CR8","doi-asserted-by":"publisher","unstructured":"Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, Burgos-Vargas R, Penades IC, Silverman ED, Espada G, Zavaler MF, Kimura Y, Duarte C, Job-Deslandre C, Joos R, Douglass W, Wimalasundera S, Bharucha KN, Wells C, Lovell DJ \u2026 Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2021). Efficacy and safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the open-label two-year extension of a phase III trial. Arthritis Rheumatol (Hoboken N J), 73(3), 530\u2013541. https:\/\/doi.org\/10.1002\/art.41528","DOI":"10.1002\/art.41528"},{"issue":"6","key":"5711_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.5114\/reum.2020.102010","volume":"58","author":"O Boyarchuk","year":"2020","unstructured":"Boyarchuk O, Kovalchuk T, Kovalchuk N, Chubata O (2020) Clinical variability of the systemic juvenile idiopathic arthritis course: literature review based on case series. Reumatologia 58(6):436\u2013443. https:\/\/doi.org\/10.5114\/reum.2020.102010","journal-title":"Reumatologia"},{"issue":"6","key":"5711_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-013-0053-1","volume":"15","author":"JE Frampton","year":"2013","unstructured":"Frampton JE (2013) Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis. Paediatr Drugs 15(6):515\u2013531. https:\/\/doi.org\/10.1007\/s40272-013-0053-1","journal-title":"Paediatr Drugs"},{"issue":"9","key":"5711_CR11","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"F de Benedetti","year":"1991","unstructured":"de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34(9):1158\u20131163. https:\/\/doi.org\/10.1002\/art.1780340912","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5711_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"V Oldfield","year":"2009","unstructured":"Oldfield V, Dhillon S, Plosker GL (2009) Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 69(5):609\u2013632. https:\/\/doi.org\/10.2165\/00003495-200969050-00007","journal-title":"Drugs"},{"issue":"9617","key":"5711_CR13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet (London England) 371(9617):998\u20131006. https:\/\/doi.org\/10.1016\/S0140-6736(08)60454-7","journal-title":"Lancet (London England)"},{"key":"5711_CR14","doi-asserted-by":"publisher","first-page":"735846","DOI":"10.3389\/fped.2021.735846","volume":"9","author":"X Yan","year":"2021","unstructured":"Yan X, Tang W, Zhang Z, Zhang Y, Luo C, Tang X (2021) Tocilizumab in systemic juvenile idiopathic arthritis: response differs by Disease Duration at Medication Initiation and by phenotype of Disease. Front Pead 9:735846. https:\/\/doi.org\/10.3389\/fped.2021.735846","journal-title":"Front Pead"},{"issue":"3","key":"5711_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/art.10863","volume":"48","author":"HE Foster","year":"2003","unstructured":"Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48(3):767\u2013775. https:\/\/doi.org\/10.1002\/art.10863","journal-title":"Arthritis Rheum"},{"issue":"3","key":"5711_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/art.20946","volume":"52","author":"F de Benedetti","year":"2005","unstructured":"de Benedetti F, Martini A (2005) Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 52(3):687\u2013693. https:\/\/doi.org\/10.1002\/art.20946","journal-title":"Arthritis Rheum"},{"key":"5711_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/OARRR.S21969","volume":"4","author":"M Murakami","year":"2012","unstructured":"Murakami M, Tomiita M, Nishimoto N (2012) Tocilizumab in the treatment of systemic juvenile idiopathic arthritis. Open Access Rheumatology: Res Reviews 4:71\u201379. https:\/\/doi.org\/10.2147\/OARRR.S21969","journal-title":"Open Access Rheumatology: Res Reviews"},{"issue":"6","key":"5711_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1759720X12455960","volume":"4","author":"S Yokota","year":"2012","unstructured":"Yokota S, Tanaka T, Kishimoto T (2012) Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Therapeutic Adv Musculoskelet Disease 4(6):387\u2013397. https:\/\/doi.org\/10.1177\/1759720X12455960","journal-title":"Therapeutic Adv Musculoskelet Disease"},{"issue":"2","key":"5711_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1586\/ecp.13.1","volume":"6","author":"X Zhang","year":"2013","unstructured":"Zhang X, Morcos PN, Saito T, Terao K (2013) Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 6(2):123\u2013137. https:\/\/doi.org\/10.1586\/ecp.13.1","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"5711_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/14740338.2017.1303479","volume":"16","author":"SH Machado","year":"2017","unstructured":"Machado SH, Xavier RM (2017) Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Exp Opin Drug Saf 16(4):493\u2013500. https:\/\/doi.org\/10.1080\/14740338.2017.1303479","journal-title":"Exp Opin Drug Saf"},{"issue":"1","key":"5711_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.46497\/ArchRheumatol.2021.7953","volume":"36","author":"A Adrovic","year":"2020","unstructured":"Adrovic A, Yildiz M, K\u00f6ker O, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6 (2020) Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review. Archives Rheumatol 36(1):146\u2013157. https:\/\/doi.org\/10.46497\/ArchRheumatol.2021.7953","journal-title":"Archives Rheumatol"},{"issue":"1","key":"5711_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A (2016) Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Therapy 18(1):272. https:\/\/doi.org\/10.1186\/s13075-016-1170-3","journal-title":"Arthritis Res Therapy"},{"issue":"6","key":"5711_CR23","doi-asserted-by":"publisher","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"P Woo","year":"2005","unstructured":"Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T (2005) Open label phase II trial of single, ascending doses of MRA in caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Therapy 7(6):R1281\u2013R1288. https:\/\/doi.org\/10.1186\/ar1826","journal-title":"Arthritis Res Therapy"},{"issue":"25","key":"5711_CR24","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, I Brunner H, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis [published correction appears in N Engl J Med, 2015, February 26; 372(9), 887]. N Engl J Med 367(25):2385\u20132395. https:\/\/doi.org\/10.1056\/NEJMoa1112802","journal-title":"N Engl J Med"},{"issue":"6","key":"5711_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-P\u00e9rez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Pediatric Rheumatology Collaborative Study Group (PRCSG) (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110\u20131117. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205351","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5711_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s10067-018-4071-9","volume":"37","author":"V Opoka-Winiarska","year":"2018","unstructured":"Opoka-Winiarska V, \u017buber Z, Alexeeva E, Chasnyk V, Nikishina I, D\u0119bowska G, Smolewska E (2018) Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial. Clin Rheumatol 37(7):1807\u20131816. https:\/\/doi.org\/10.1007\/s10067-018-4071-9","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5711_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1517\/14712598.2016.1150997","volume":"16","author":"JL Turnier","year":"2016","unstructured":"Turnier JL, Brunner HI (2016) Tocilizumab for treating juvenile idiopathic arthritis. Expert Opin Biol Ther 16(4):559\u2013566. https:\/\/doi.org\/10.1517\/14712598.2016.1150997","journal-title":"Expert Opin Biol Ther"},{"key":"5711_CR28","doi-asserted-by":"publisher","unstructured":"Boxer LA (2012) How to approach neutropenia. Hematology. American Society of Hematology. Education Program, 2012, 174\u2013182. https:\/\/doi.org\/10.1182\/asheducation-2012.1.174","DOI":"10.1182\/asheducation-2012.1.174"},{"issue":"4","key":"5711_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple R (2006) Hy\u2019s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15(4):241\u2013243. https:\/\/doi.org\/10.1002\/pds.1211","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5711_CR30","unstructured":"National Cancer Institute (2006), August Common Terminology Criteria for Adverse Events v3.0 (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"issue":"1","key":"5711_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","volume":"14","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Giancane G, Schiappapietra B, Dav\u00ec S, Calandra S, Lanni S, Ravelli A (2016) Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 14(1):23. https:\/\/doi.org\/10.1186\/s12969-016-0085-5","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"5711_CR32","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/annrheumdis-2013-204186","volume":"73","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, Verazza S, Negro G, Gerloni V, Goldenstein-Schainberg C, Sztajnbok F, Wulffraat NM, Martini A, Ravelli A, Paediatric Rheumatology International Trials Organization (PRINTO) (2014) Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 73(7):1380\u20131383. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204186","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5711_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43166-021-00074-1","volume":"48","author":"MA Muzaffer","year":"2021","unstructured":"Muzaffer MA, Abdelgalil AA (2021) Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at a tertiary university hospital. Egypt Rheumatol Rehabilitation 48(1):1\u20137. https:\/\/doi.org\/10.1186\/s43166-021-00074-1","journal-title":"Egypt Rheumatol Rehabilitation"},{"key":"5711_CR34","unstructured":"National Institutes of Health (2023) Tocilizumab in patients with juvenile idiopathic arthritis. ClinicalTrials.gov. Retrieved March 25, 2023, from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00774646"},{"issue":"1","key":"5711_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","volume":"19","author":"G Horneff","year":"2017","unstructured":"Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP (2017) Experience with etanercept, tocilizumab and interleukin\u20131 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Therapy 19(1):256. https:\/\/doi.org\/10.1186\/s13075-017-1462-2","journal-title":"Arthritis Res Therapy"},{"key":"5711_CR36","doi-asserted-by":"publisher","unstructured":"Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S (2016) Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 75(9):1654\u20131660. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207818","DOI":"10.1136\/annrheumdis-2015-207818"},{"issue":"4","key":"5711_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","volume":"55","author":"S Tarp","year":"2016","unstructured":"Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, Pope TD, Furst DE (2016) Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford) 55(4):669\u2013679. https:\/\/doi.org\/10.1093\/rheumatology\/kev382","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5711_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3899\/jrheum.180795","volume":"46","author":"M Pardeo","year":"2019","unstructured":"Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Kon\u00e9-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F, the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2019) Neutropenia during Tocilizumab Treatment is not Associated with infection risk in systemic or polyarticular-course Juvenile Idiopathic Arthritis. J Rhuematol 46(9):1117\u20131126. https:\/\/doi.org\/10.3899\/jrheum.180795. Paediatric Rheumatology International Trials Organisation (PRINTO)","journal-title":"J Rhuematol"},{"key":"5711_CR39","doi-asserted-by":"publisher","unstructured":"Shimizu M, Mizuta M, Okamoto N, Yasumi T, Iwata N, Umebayashi H, Okura Y, Kinjo N, Kubota T, Nakagishi Y, Nishimura K, Mohri M, Yashiro M, Yasumura J, Wakiguchi H, Mori M (2020) Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 18(1):2. https:\/\/doi.org\/10.1186\/s12969-020-0399-1","DOI":"10.1186\/s12969-020-0399-1"},{"issue":"3","key":"5711_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5114\/reum.2021.107590","volume":"59","author":"O Boyarchuk","year":"2021","unstructured":"Boyarchuk O, Predyk L, Yuryk I (2021) COVID\u201319 in patients with juvenile idiopathic arthritis: frequency and severity. Reumatologia 59(3):197\u2013199. https:\/\/doi.org\/10.5114\/reum.2021.107590","journal-title":"Reumatologia"},{"issue":"6","key":"5711_CR41","first-page":"1271","volume":"38","author":"M Yildiz","year":"2020","unstructured":"Yildiz M, Haslak F, Adrovic A, Sahin S, Barut K, Kasapcopur O (2020) The frequency and clinical course of COVID\u201319 infection in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 38(6):1271\u20131272","journal-title":"Clin Exp Rheumatol"},{"key":"5711_CR42","doi-asserted-by":"publisher","unstructured":"Sengler C, Eulert S, Minden K, Niewerth M, Horneff G, Kuemmerle-Deschner J, Siemer C, Berendes R, Girschick H, H\u00fchn R, Borte M, Hospach A, Emminger W, Armann J, Klein A, Kallinich T (2021) Clinical manifestations and outcome of SARS-CoV\u20132 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD open 7(2):e001687. https:\/\/doi.org\/10.1136\/rmdopen-2021-001687","DOI":"10.1136\/rmdopen-2021-001687"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05711-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:05:04Z","timestamp":1733310304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05711-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5711"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05711-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}